SITE002-0062

SITE002 (USA) › SITE002-0062

SITE002-0062

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2025-11-09

enrolled

AEs

9

Serious

1

Dropout signal

–

Adverse events

9

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 116); relationship: RELATED

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-13 (study day 113); relationship: RELATED

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-21 (study day 90); relationship: not assessed

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-21 (study day 59); relationship: NOT RELATED

mild assessed

Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2022-07-07 (study day 45); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 36); relationship: RELATED

mild assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 30); relationship: NOT RELATED

moderate assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 30); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-02 (study day 10); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.